Sanjeev Luther, president and chief executive officer (CEO) of Rafael Pharmaceuticals talks about his company’s lead compound, PI-613 (devimistat).
PI-613 targets enzymes involved in cancer cell energy metabolism located in the mitochondria of cancer cells. This drug is being investigated in a number of rare cancers, including metastatic pancreatic cancer and refractory acute myeloid leukemia (AML).
Pancreatic cancer is an extremely deadly disease. Although it is a rare cancer, it is one of the more common causes of cancer death. One reason for that is that most people who have the condition are not diagnosed until the disease has significantly advanced. It is estimated that the 5-year survival rate of patients with metastatic (stage IV) pancreatic cancer is only 3% and as such, there is a great medical need to find a more effective first-line therapy for this condition.
PI-613 is currently being investigated in a phase III clinical trial testing its efficacy and safety in patients with metastatic pancreatic cancer.
AML is a rare blood cancer with numerous front-line treatments available. Unfortunately, most patients with AML will relapse and treatment options become more limited.
PI-613 is currently being investigated in a phase III clinical trial testing its efficacy and safety in patients with relapsed or refractory AML.
For more information, visit rafaelpharma.com